Related Experiment Video

Updated: May 21, 2026

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer
08:34

Utilizing Murine Inducible Telomerase Alleles in the Studies of Tissue Degeneration/Regeneration and Cancer

Published on: April 13, 2015

Gemcitabine causes telomere attrition by stabilizing TRF2

Chih-Hao Su1, Wei-Chih Chu, Keng-Hsin Lan

  • 1Institute of Biochemistry and Molecular Biology, National Yang-Ming University, No. 155 Sec 2 Linong St., Taipei, Taiwan.

European Journal of Cancer (Oxford, England : 1990)
|June 19, 2012
PubMed

Insights

Gemcitabine, an anti-cancer drug, shortens telomeres by stabilizing TRF2, leading to DNA damage and tumor growth inhibition. This novel mechanism reveals a new way gemcitabine fights cancer beyond DNA synthesis inhibition.

Area of Science:

  • Oncology
  • Molecular Biology
  • Genetics

Background:

  • Gemcitabine is a key chemotherapy drug for solid tumors.
  • Its primary mechanism involves DNA synthesis inhibition.
  • The role of gemcitabine in tumor growth inhibition beyond DNA incorporation is unclear.

Purpose of the Study:

  • To investigate novel anti-tumor mechanisms of gemcitabine.
  • To explore gemcitabine's effect on telomeres and associated proteins.

Main Methods:

  • Cellular assays to assess gemcitabine's impact on telomere length.
  • Analysis of TRF2 protein stabilization and its interaction with XPF/ERCC1.
  • Investigating telomere shortening induced by TRF2 overexpression.

Main Results:

  • Gemcitabine induces telomere shortening by stabilizing TRF2.
  • Stabilized TRF2 is essential for XPF-dependent telomere loss.
  • Overexpression of TRF2 alone also causes telomere shortening and associates with XPF/ERCC1.

Conclusions:

  • Gemcitabine exhibits anti-tumor activity through a novel mechanism involving telomere shortening.
  • TRF2 stabilization and subsequent XPF-dependent telomere loss are key components of this pathway.
  • This finding expands our understanding of gemcitabine's therapeutic effects in cancer treatment.

More Related Videos

Analyzing Telomeric Protein-DNA Interactions Using Single-Molecule Magnetic Tweezers11:21

Analyzing Telomeric Protein-DNA Interactions Using Single-Molecule Magnetic Tweezers

Published on: August 30, 2024

Optimization of Performance Parameters of the TAGGG Telomere Length Assay08:23

Optimization of Performance Parameters of the TAGGG Telomere Length Assay

Published on: April 21, 2023

Related Concept Videos

Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Telomeres and Telomerase02:41

Telomeres and Telomerase

In eukaryotic DNA replication, a single-stranded DNA fragment remains at the end of a chromosome after the removal of the final primer. This section of DNA cannot be replicated in the same manner as the rest of the strand because there is no 3’ end to which the newly synthesized DNA can attach. This non-replicated fragment results in gradual loss of the chromosomal DNA during each cell duplication. Additionally, it can induce a DNA damage response by enzymes that recognize single-stranded DNA.
Replicative Cell Senescence02:15

Replicative Cell Senescence

Replicative cell senescence is a property of cells that allows them to divide a finite number of times throughout the organism's lifespan while preventing excessive proliferation. Replicative senescence is associated with the gradual loss of the telomere — short, repetitive DNA sequences found at the end of the chromosomes. Telomeres are bound by a group of proteins to form a protective cap on the ends of chromosomes. Embryonic stem cells express telomerase — an enzyme that adds the telomeric...
Drugs that Stabilize Microtubules01:15

Drugs that Stabilize Microtubules

Microtubules are dynamic structures that undergo cycles of catastrophe and rescue. The microtubules play a central role in cell division by forming the spindle apparatus for segregating the chromosomes. This makes them ideal targets for regulating dividing cells in tumors and malignant cancer cells. Microtubule stabilizing drugs help stabilize the microtubule formation and promote its polymerization. Paclitaxel was the first microtubule stabilizing agent used as anticancer drug in chemotherapy...
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...